BR0315293A - Derivados de lactona para o tratamento de hiperparatireoidismo - Google Patents

Derivados de lactona para o tratamento de hiperparatireoidismo

Info

Publication number
BR0315293A
BR0315293A BR0315293-6A BR0315293A BR0315293A BR 0315293 A BR0315293 A BR 0315293A BR 0315293 A BR0315293 A BR 0315293A BR 0315293 A BR0315293 A BR 0315293A
Authority
BR
Brazil
Prior art keywords
hyperparathyroidism
treatment
lactone derivatives
derivatives
animal
Prior art date
Application number
BR0315293-6A
Other languages
English (en)
Inventor
Eugene A Woltering
Original Assignee
Univ Louisiana State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisiana State filed Critical Univ Louisiana State
Publication of BR0315293A publication Critical patent/BR0315293A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"DERIVADOS DE LACTONA PARA O TRATAMENTO DE HIPERPARATIREOIDISMO". A presente invenção refere-se a um método de tratamento de um animal de sangue quente, especialmente um ser humano, que apresenta hiperparatireoidismo, método este que compreende administrar a esse animal uma quantidade terapeuticamente eficaz de um derivado de epotilona de fórmula I ou um sal farmaceuticamente aceitável desse derivado.
BR0315293-6A 2002-10-15 2003-10-13 Derivados de lactona para o tratamento de hiperparatireoidismo BR0315293A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41859202P 2002-10-15 2002-10-15
PCT/IB2003/004514 WO2004035050A1 (en) 2002-10-15 2003-10-13 Use of epothilone derivatives for the treatment of hyperparathyroidism

Publications (1)

Publication Number Publication Date
BR0315293A true BR0315293A (pt) 2005-08-30

Family

ID=32107949

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315293-6A BR0315293A (pt) 2002-10-15 2003-10-13 Derivados de lactona para o tratamento de hiperparatireoidismo

Country Status (16)

Country Link
US (2) US20060142354A1 (pt)
EP (1) EP1553938B1 (pt)
JP (1) JP4672368B2 (pt)
CN (1) CN1297269C (pt)
AT (1) ATE350034T1 (pt)
AU (1) AU2003267751A1 (pt)
BR (1) BR0315293A (pt)
CA (1) CA2501717C (pt)
CY (1) CY1106385T1 (pt)
DE (1) DE60310975T2 (pt)
DK (1) DK1553938T3 (pt)
ES (1) ES2279139T3 (pt)
HK (1) HK1080768A1 (pt)
PT (1) PT1553938E (pt)
SI (1) SI1553938T1 (pt)
WO (1) WO2004035050A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2281692T3 (es) 2002-08-23 2007-10-01 Sloan-Kettering Institute For Cancer Research Sintesis de epotilones, sus intermediarios, sus analogos y sus usos.
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ533467A (en) * 1993-07-19 2006-02-24 Angiotech Pharm Inc Anti-angiogenic compositions and methods of use
HU229833B1 (en) * 1996-11-18 2014-09-29 Biotechnolog Forschung Gmbh Epothilone d production process, and its use as cytostatic as well as phytosanitary agents
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
BR9907647B1 (pt) * 1998-02-05 2014-04-01 Novartis Ag Novartis S A Novartis Inc Formulação farmacêutica na forma de um concentrado para infusão, o qual deve ser diluído antes da administração, e solução para infusão
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones

Also Published As

Publication number Publication date
CA2501717C (en) 2012-09-18
DK1553938T3 (da) 2007-03-26
WO2004035050A1 (en) 2004-04-29
EP1553938A1 (en) 2005-07-20
DE60310975T2 (de) 2007-07-12
JP2006504751A (ja) 2006-02-09
US20110152329A1 (en) 2011-06-23
ATE350034T1 (de) 2007-01-15
CN1297269C (zh) 2007-01-31
JP4672368B2 (ja) 2011-04-20
CN1703217A (zh) 2005-11-30
AU2003267751A1 (en) 2004-05-04
EP1553938B1 (en) 2007-01-03
PT1553938E (pt) 2007-03-30
US20060142354A1 (en) 2006-06-29
CA2501717A1 (en) 2004-04-29
ES2279139T3 (es) 2007-08-16
CY1106385T1 (el) 2011-10-12
SI1553938T1 (sl) 2007-06-30
DE60310975D1 (de) 2007-02-15
HK1080768A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
BR0312729A (pt) Novos derivados de indol-3-enxofre
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
AR037595A1 (es) Metodos de tratamiento y formulaciones de cefalosporina
DE60325379D1 (de) Zusammensetzung enthaltend 6-Ä3-(1-adamantyl)-4-methoxyphenylÜ-2-naphthanoesäure zur Behandlung dermatologischer Erkrankungen
BR0310092A (pt) Combinação de compostos orgânicos
PT1213296E (pt) Derivados de glucopiranosiloxipirazole composicoes medicas que os contem e intermediarios na sua producao
DK1780197T3 (da) 5-Substituerede 2-phenylamino-benzamider som MEK-inhibitorer
BR0309355A (pt) 2-(2,6-diclorofenil)-diarilimidazóis
ATE496048T1 (de) Phenylcarboxamidverbindungen zur schmerzbehandlung
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
DE69940951D1 (de) Nd wachstumshemmende mittel
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
EP1627635A3 (en) Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection
IT1311922B1 (it) Composti farmaceutici.
DE60219614D1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
BRPI0509653A (pt) inibidores cinesina mitótica
ES2136252T3 (es) Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa.
BR0307588A (pt) Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
BR0211203A (pt) Acilsemicarbazidas como inibidores de cinase dependente de ciclina úteis como agentes anti-câncer e anti-proliferativos
BR0311801A (pt) Composição de imidazol, método para produção do mesmo, composição farmacêutica, embalagem comercial, método para a profilaxia ou tratamento de doenças, método para erradicar helicobacter pylori de um animal infectado com helicobacter pylori, e, uso de um composto
ES2134313T3 (es) Utilizacion de derivados de pregnano para el tratamiento de tumores.
BR0010225A (pt) Composto de amida, processo para prepará-lo, composição farmacêutica compreendendo dito composto, método de tratamento e uso

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014.